GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (STU:7RG0) » Definitions » YoY EPS Growth

Regulus Therapeutics (STU:7RG0) YoY EPS Growth : 53.80% (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regulus Therapeutics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Regulus Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2024 was 53.80%.

Regulus Therapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was €-0.16.

Regulus Therapeutics YoY EPS Growth Historical Data

The historical data trend for Regulus Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics YoY EPS Growth Chart

Regulus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.22 61.94 22.49 38.75 17.48

Regulus Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.70 25.74 5.29 31.89 53.80

Regulus Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Regulus Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-1.449--1.756)/ | -1.756 |
=17.48 %

Regulus Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EPS Growth (Q: Jun. 2024 )
=(Earnings per Share (Diluted) (Q: Jun. 2024 )-Earnings per Share (Diluted) (Q: Jun. 2023 )) / | Earnings per Share (Diluted) (Q: Jun. 2023 )) |
=(-0.158--0.342)/ | -0.342 |
=53.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regulus Therapeutics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Regulus Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (STU:7RG0) » Definitions » YoY EPS Growth
Comparable Companies
ENLV CRBP VIRX CRIS ORGS CLRB AGE MRKR CLCS AURX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
RGLS:USA
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Website
https://www.regulusrx.com
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Regulus Therapeutics Headlines

No Headlines